English (United States)

About the MARITIME-HF study

MARITIME-HF is a Phase 3 study for people who are living with heart failure (HF) and obesity. In this study, we are exploring if an investigational medicine (a monthly injection) can help to reduce HF-related symptoms and risk of hospitalization. 

Who can take part?

Amgen is currently recruiting for this trial.

You, or someone you care for, may be able to take part if you/they:

  • are 18 years of age or older 
  • are living with HF and are receiving treatment for it
  • are living with obesity, which means having a body mass index (BMI) of 30 kg/m2 or more.

What will this study involve?

The MARITIME-HF study will last up to 5.5 years. Participants will receive either the investigational medicine or a placebo, which contains no actual medicine. A placebo looks the same as the investigational medicine.


The study is divided into 2 parts that will be performed one after the other. Part 1 of the study is expected to last up to 3.5 years and Part 2 for 2 years.

Screening period

(up to 4 weeks)

PARTICIPANT RESPONSIBILITIES:

  • Visit the study center to see if you meet the requirements for this study

Study treatment period 


(2 parts) (about 1- 5 years)

PARTICIPANT RESPONSIBILITIES:

  • You will have regular visits to the study center for study assessments
  • In Part 1, you will receive the investigational medicine or placebo as a monthly injection.
  • Everyone who completes Part 1 will have the option to join Part 2 and receive the investigational medicine for 2 years.
  • If you decide not to enter Part 2, you will enter the follow-up period.

Follow-up period

(about 4 months)




PARTICIPANT RESPONSIBILITIES:

  • Visit the study center once more for study assessments